Page 1

Investor Contact : Arthur Shannon arthur.shannon@bauschhealth.com ( 514 ) 856-3855 ( 877 ) 281-6642 ( toll free ) BAUSCH Health Media Contact : Lainie Keller lainie.keller@bauschhealth.com ( 908 ) 927-1198 BAUSCH HEALTH COMPANIES INC . ANNOUNCES SECOND - QUARTER 2021 RESULTS Second - Quarter 2021 Financial Results • ○ Revenues of $ 2.100 Billion ○ GAAP Net Loss of $ 595 Million • ○ Adjusted EBITDA ( non - GAAP ) ¹ of $ 826 Million GAAP Cash Generated from Operations of $ 395 Million Thomas J. Appio Appointed CEO of Bausch Pharma² Bausch Health Announced Plans to Pursue an Initial Public Offering for Solta Medical³ Revised 2021 Full - Year Revenue and Adjusted EBITDA ( non - GAAP ) Guidance Ranges , Primarily to Reflect Amoun Pharmaceutical Divestiture LAVAL , Quebec , Aug. 3 , 2021 - Bausch Health Companies Inc. ( NYSE / TSX : BHC ) ( " Bausch Health " or the " Company " or " we " ) today announced its second - quarter 2021 financial results . " Our second - quarter 2021 results demonstrate impressive overall company growth as our businesses continue to recover from the COVID - 19 pandemic , ” said Joseph C. Papa , chairman and CEO , Bausch Health . " We saw strong performance with market share gains for many of our leading brands and strong cash flow generation in the quarter , which has enabled us to make great strides in reducing our debt . " " Today we announced our plans to pursue an initial public offering for our Solta Medical business³ , which is an important step in the previously announced spinoff of the Bausch + Lomb eye health business , resulting in the creation of three attractive companies : Bausch + Lomb , a pure - play , integrated eye health company ; Bausch Pharma² , a global diversified pharmaceuticals business ; and Solta Medical , a leading global provider in medical aesthetics . We remain committed to unlocking value across these three attractive businesses as soon as possible , " continued Mr. Papa . Select Company Highlights • Increased total Company reported revenue by 26 % compared to the second quarter of 2020 • Expanded launch of ENVIVE ™ , a daily over - the - counter probiotic supplement , in the United States Launched expanded parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses • • Completed divestiture of Amoun Pharmaceutical Company S.A.E. to Abu - Dhabi - based ADQ Repaid debt by $ 500 million in the first half of 2021 using cash generated from operations ; Bausch Health has no debt maturities until 2025 1 Please see the tables at the end of this news release for a reconciliation of this and other non - GAAP measures to the nearest comparable GAAP measure . 2 The remainder of Bausch Health is referred to as " Bausch Pharma " and will assume a new name upon the separation of the Company's eye health business , Bausch + Lomb . 3 This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities .